Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

By BioPharma Dive staff • May 20, 2025

Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot

CEO Keith Gottesdiener will be replaced by Prime's CFO as the company cuts 25% of its workforce and deprioritizes its lead program.

By Gwendolyn Wu • May 19, 2025

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Novavax’s COVID vaccine gets FDA approval, but with limits

While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the company.

By Delilah Alvarado • May 19, 2025

Regeneron wins bid to buy 23andMe out of bankruptcy

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

By Ned Pagliarulo • May 19, 2025

Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and the FDA scheduled an advisory meeting.

By Ben Fidler • May 16, 2025

A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months. 

By Ben Fidler • May 15, 2025

FDA delays approval decision for Biohaven rare disease drug

Shares of the biotech fell around 15% on news the FDA is not only taking longer to review the drug, but will assemble an outside group of advisers to evaluate it as well.

By Jacob Bell • May 15, 2025

AbbVie stakes $335M on a startup’s RNAi drugs

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer. 

By Gwendolyn Wu • May 15, 2025

GSK to buy liver disease drug for $1.2B

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

By Kristin Jensen • May 14, 2025

Bluebird extends deal deadline; Affimed files for insolvency

Shareholders in Bluebird now have a choice of two offers from would-be acquirers Carlyle and SK Capital. Elsewhere, Cytokinetics shared more aficamten data and BridgeBio started a new kind of Attruby trial.

By BioPharma Dive staff • May 14, 2025

Galapagos backtracks on planned split

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic options and “transformative” deals.

By Jacob Bell • May 13, 2025

iTeos, GSK to shelve TIGIT drug after study setback

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic review in response. 

By Ben Fidler • May 13, 2025

FDA follows EMA in limiting use of Valneva shot

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and now the U.S. to suspend use in older adults pending an investigation.

By Delilah Alvarado • May 12, 2025

Innovating a healthier tomorrow: Entering a new era of medicine

Explore the cutting-edge of science and learn how Danaher is advancing healthcare innovation

May 12, 2025

Eli Lilly extends Purdue alliance; EMA investigates Valneva shot

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

By BioPharma Dive staff • May 9, 2025

4 more biotechs cut staff amid market tumult

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job cuts for a sector struggling to hold its financial footing. 

By Ben Fidler • May 8, 2025

Haya banks $65M to scour the ‘dark genome’ for new drugs

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed by Bristol Myers and Cytokinetics.

By Ben Fidler • May 8, 2025

Sarepta shares plummet as lower sales outlook adds to gloom over FDA’s new biologics hire

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less friendly FDA.

By Kristin Jensen • May 7, 2025

Bluebird pleads for deal support; Unity, Mersana lay off staff

Bluebird urged shareholders to back a take-private deal that could close imminently. Elsewhere, Unity Biotechnology began a strategic review and Mersana announced plans to cut more than half its workforce.

By BioPharma Dive staff • May 6, 2025

PTC stock slides on new data for Huntington’s drug

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less clear-cut.

By Ned Pagliarulo • May 5, 2025

AI specialist Recursion trims pipeline in latest shakeup

The cuts to three advanced drug programs were “inevitable” given the company’s “unsustainable cash burn,” one analyst wrote in a note to investors. 

By Delilah Alvarado • May 5, 2025

Deerfield secures more than $600M for its next biotech venture fund

The firm, a prolific backer of drug startups, will use the cash to back companies working on therapeutics, medical devices and healthcare services.

By Ben Fidler • May 5, 2025

Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma

The FDA pushed back its decision date on Cytokinetics’ heart drug. Elsewhere, Repare Therapeutics licensed its drug discovery work, intellectual property and certain other assets into a newly launched startup.

By BioPharma Dive staff • May 2, 2025

Moderna combination flu, COVID shot delayed amid FDA scrutiny

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

By Delilah Alvarado • May 1, 2025

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics production plant.

By BioPharma Dive staff • May 1, 2025